1. "2015"
  2. "Martin Tallman"
Formats
  1. Meeting Abstract (38)
  2. Journal Article (25)
  3. Book Section (1)
Groups
  1. Adult Leukemia (64)
  2. Center for Hematologic Malignancies (64)
  3. Department of Medicine (64)
  4. Hematologic Malignancies, Division of (64)
  5. Executive Committee, Center for Hematologic Malignancies (21)
  6. GSK Faculty (21)

More Groups

People
  1. Martin Tallman (64)
  2. Ross Levine (18)
  3. Eytan Stein (10)
  4. Omar Abdel-Wahab (8)
  5. Sean Devlin (7)
  6. Dan Douer (6)

More People

Years
  1. 2015 (64)
Publications
  1. Blood (30)
  2. Clinical Lymphoma, Myeloma and Leukemia (5)
  3. Journal of Clinical Oncology (4)
  4. Haematologica (3)
  5. Leukemia (3)
  6. Biology of Blood and Marrow Transplantation (2)

More Publications

Publishers
  1. American Society of Hematology (30)
  2. Elsevier Inc. (8)
  3. Nature Publishing Group (5)
  4. American Society of Clinical Oncology (4)
  5. Ferrata Storti Foundation (3)
  6. John Wiley & Sons (2)

More Publishers

Results (64)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Acute promyelocytic leukemia: Where did we start, where are we now, and the future
    Journal Article

    Coombs, C. C.; Tavakkoli, M.; Tallman, M. S.
    Blood Cancer Journal (2015)

    Fulltext@MSK | Save
  • Clinical description of acute promyelocytic leukemia (APL) patients receiving all-trans retinoic acid (ATRA) who develop pseudotumor cerebri: Incidence, diagnosis, outcomes, and recommendations for management
    Meeting Abstract

    Coombs, C. C.; DeAngelis, L. M.; Feusner, J. H.; Tallman, M. S.
    Clinical Lymphoma, Myeloma and Leukemia (2015)

    Fulltext@MSK | Save
  • Delays in intensification are common in adults with acute lymphoblastic leukemia (ALL), are associated with decreased survival in allogeneic hematopoietic cell transplant (HCT) patients
    Meeting Abstract

    Kumar, A.; Gimotty, P.; Gelfand, J.; Buck, G.; Rowe, J.; Goldstone, A.; Fielding, A.; Marks, D.; Litzow, M.; Paietta, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2015)

    Fulltext@MSK | Save
  • Very high dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia in the setting of intensified anthracycline induction and post stem-cell transplantation
    Meeting Abstract

    Itchaki, G.; Wolach, O.; Bar-Natan, M.; Yeshurun, M.; Ram, R.; Herscovici, C.; Douer, D.; Tallman, M.; Shpilberg, O.; Raanani, P.
    Clinical Lymphoma, Myeloma and Leukemia (2015)

    Fulltext@MSK | Save
  • Astarabine, a pro-drug of cytarabine, is safe for patients with advanced acute leukemia. A phase I/IIa single center study in relapsed/refractory or medically unfit patients
    Meeting Abstract

    Zuckerman, T.; Ben Yakar, R.; Gengrinovitch, S.; Hoffman, R.; Henig, I.; Lavi, N.; Akria, L.; Ofran, Y.; Nudelman, O.; Haddad, N.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • A phase 1 study of the DOT1L inhibitor, pinometostat (EPZ-5676), in adults with relapsed or refractory leukemia: Safety, clinical activity, exposure and target inhibition
    Meeting Abstract

    Stein, E. M.; Garcia-Manero, G.; Rizzieri, D. A.; Tibes, R.; Berdeja, J. G.; Jongen-Lavrencic, M.; Altman, J. K.; Dohner, H.; Thomson, B.; Blakemore, S. J.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • The aberrantly expressed long noncoding RNA, TRERNA1, predicts for aggressive disease in chronic lymphocytic leukemia
    Meeting Abstract

    Miller, C. R.; Ruppert, A. S.; Coombes, K.; Lehman, A. M.; Blachly, J. S.; Lucas, D. M.; Grever, M. R.; Tallman, M. S.; Flinn, I. W.; Rassenti, L. Z.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • A clinical measure of DNA methylation predicts outcome in de novo AML
    Meeting Abstract

    Luskin, M. R.; Gimotty, P.; Smith, C.; Loren, A.; Figueroa, M.; Harrison, J.; Sun, Z. X.; Tallman, M. S.; Paietta, E.; Litzow, M. R.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • High response rate of moxetumomab pasudotox in relapsed/refractory hairy cell leukemia includes eradication of minimal residual disease: Potential importance for outcome
    Meeting Abstract

    Kreitman, R. J.; Arons, E.; Tallman, M. S.; Tadeusz, R.; Coutre, S.; Wilson, W. H.; Stetler-Stevenson, M.; Yuan, C. M.; Lanasa, M.; FitzGerald, D. J. P.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • AUY922, a Heat Shock Protein 90 (Hsp90) inhibitor, demonstrates activity in patients with myeloproliferative neoplasms (MPNs)
    Meeting Abstract

    Hobbs, G.; Litvin, R.; Ahn, J.; McKenney, A. S.; Mauro, M. J.; Tallman, M. S.; Berman, E.; Heaney, M. L.; Levine, R. L.; Rampal, R. K.
    Blood (2015)

    Fulltext@MSK | Save